We'd like to think that the billions of dollars being spent annually on cancer drug development are making a sizable impact on the lives of cancer patients. But, that may not be the case, according to this latest study.
Our experts weigh in.
Motley Fool experts discuss whether Bristol-Myers Squibb's Opdivo or Merck & Co.'s Keytruda will be the bigger commercial success.
Is this meaningful or just another movement?
Pfizer recently acquired Hospira for $17 billion, but it has plenty of fuel left to go after more deals to boost its pipeline and shareholder value.
Utilizing the body's immune system to help fight cancer is among the latest techniques researchers are using. However, this team of researchers has developed a truly unique new way of combating cancer.
Did researchers really uncover the mechanism behind intestinal cancer formation? Find out what game-changing news this latest study brings to light and how this could help drug developers plan their attack against intestinal cancers.
Pharmacyclics, Celgene Corp., Bristol-Myers Squibb, and Pfizer could see sales of new drugs eclipse $1 billion this year.
Motley Fool experts highlight three blockbuster-selling therapies that could fall by the wayside in the next five years.
Bristol-Myers Squibb this week held a conference call to discuss its fourth-quarter and full-year results. Here are five things management wants investors to know.